Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: CRS/HIPEC Cannot be Done—Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baron E, Milovanov V, Gushchin V, Sittig M, Neiroda C, Sardi A. Predicting aborted hyperthermic intraperitoneal chemotherapy (AHIPEC) with preoperative tumor and inflammatory markers in potentially resectable appendiceal cancer patients with peritoneal carcinomatosis. Ann Surg Oncol. 2020;27(7):2548–56. https://doi.org/10.1245/s10434-019-08117-w.

    Article  PubMed  Google Scholar 

  2. Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116(2):316–22.

    Article  Google Scholar 

  3. Asare EA, Compton CC, Hanna NN, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer. 2016;122(2):213–21.

    Article  Google Scholar 

  4. Baron E, Sardi A, King MC, et al. Systemic chemotherapy for high-grade mucinous appendiceal cancer with peritoneal spread after unsuccessful CRS/HIPEC. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-11894-6.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tokunaga R, Xiu J, Johnston C, et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clin Cancer Res. 2019;25(10):3096–103.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA

    Ekaterina Baron MD, Mary Caitlin King BS, Vadim Gushchin MD, FACS & Armando Sardi MD, FACS

  2. Department of Medical Oncology and Hematology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA

    Panayotis Ledakis MD

Authors
  1. Ekaterina Baron MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Caitlin King BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vadim Gushchin MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Armando Sardi MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Panayotis Ledakis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Armando Sardi MD, FACS.

Ethics declarations

Disclosures

Ekaterina Baron, Mary Caitlin King, Vadim Gushchin, Armando Sardi, and Panayotis Ledakis declare no conflicts of interest regarding the publication of this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baron, E., King, M.C., Gushchin, V. et al. ASO Author Reflections: CRS/HIPEC Cannot be Done—Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer. Ann Surg Oncol 29, 6590–6591 (2022). https://doi.org/10.1245/s10434-022-11925-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-11925-2

Search

Navigation